@Article{,
AUTHOR = {Jeffrey W. Nix, Culley C. Carson},
TITLE = {Medical management of benign prostatic hypertrophy},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {14},
YEAR = {2007},
NUMBER = {Suppl.6},
PAGES = {53--57},
URL = {http://www.techscience.com/CJU/v14nSuppl.6/63321},
ISSN = {1488-5581},
ABSTRACT = {Benign prostatic hyperplasia (BPH) is a common condition
of the aging male. The bladder outlet obstruction caused by
this condition occurs despite variations in prostate size.
Symptoms of BPH include the irritative and obstructive
voiding symptoms termed lower urinary tract symptoms
(LUTS). While transurethral surgery has long been the gold
standard for treatment of LUTS, medical treatment has
emerged as the first line of treatment for those men who fail
expectant or watchful waiting treatment. Medical options
include: alpha blockers, 5α-reductase inhibitors and newly
identified PDE 5 inhibitors, drugs for erectile dysfunction
that have a relieving effect on the symptoms of LUTS.
Newer prostate selective alpha blockers have replaced
older nonselective agents as first choice in treatment of
most men, especially those with smaller prostates and in
whom preservation of sexual function is important.
While tamsulosin has the effect of an ejaculation,
alfuzosin preserves ejaculatory function. 5α-reductase
inhibitors may decrease ejaculate volume, libido and
sexual function. While this effect is frequently a self
limited, it can be a compliance issue for many men. PDE
5 inhibitors, while effective in relieving LUTS symptoms,
have not shown effectiveness in reducing post void
residual volumes or increasing urinary flow rates.},
DOI = {}
}